Ozanezumab
Ozanezumab
Ozanezumab (pronounced as o-zan-e-zu-mab) is a monoclonal antibody designed for the treatment of ALS, also known as Lou Gehrig's disease. It is developed by GlaxoSmithKline, a British multinational pharmaceutical company.
Etymology
The name Ozanezumab is derived from the International Nonproprietary Names (INN), where 'Oza' is a prefix used for monoclonal antibodies, 'nezu' is a substem used for immunomodulating monoclonal antibodies, and 'mab' is a suffix for monoclonal antibodies.
Mechanism of Action
Ozanezumab works by targeting a protein called Nogo-A, which is found in high levels in the brain and spinal cord of patients with ALS. By blocking the action of Nogo-A, Ozanezumab may help to protect nerve cells from damage and slow the progression of the disease.
Clinical Trials
Ozanezumab has been tested in clinical trials. However, in a phase II trial, it did not meet its primary endpoint of a change in the ALS Functional Rating Scale (ALSFRS-R) score. Further research is needed to determine the potential benefits and risks of this treatment.
Related Terms
- Monoclonal antibody
- Amyotrophic lateral sclerosis
- GlaxoSmithKline
- Nogo-A
- Clinical trial
- ALS Functional Rating Scale
External links
- Medical encyclopedia article on Ozanezumab
- Wikipedia's article - Ozanezumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski